{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Orthofix Medical, Inc.
Orthofix Medical Hits 52-Week Low at $9.14 Amid Market Challenges
Orthofix Medical, Inc. has reached a new 52-week low, reflecting significant stock price fluctuations over the past year. Despite achieving strong operating cash flow and reduced raw material costs, the company faces challenges, including negative return on equity and underperformance against the S&P 500, indicating a cautious financial outlook.
Orthofix Medical Hits 52-Week Low at $9.15 Amid Market Challenges
Orthofix Medical, Inc. has reached a new 52-week low, reflecting ongoing struggles with a return of -18.89% over the past year. Despite some positive operational metrics, the company faces challenges, including a negative return on equity and underperformance compared to the S&P 500, raising concerns about its financial health.
Orthofix Medical Hits 52-Week Low at $9.16 Amidst Ongoing Struggles
Orthofix Medical, Inc. has reached a new 52-week low of USD 9.16, reflecting a significant decline over the past year. The company, with a market capitalization of USD 477 million, has a low debt-to-equity ratio but reports a negative return on equity. Institutional holdings stand at 100%.
Orthofix Medical Hits 52-Week Low at $9.47 Amid Declining Profits
Orthofix Medical, Inc. has reached a new 52-week low, reflecting ongoing struggles with a -28.84% return over the past year. The company has a market capitalization of USD 477 million, a low debt-equity ratio of 0.22, and a negative return on equity of -27.08%, indicating profitability challenges.
Orthofix Medical Hits 52-Week Low at $9.52 Amidst Market Challenges
Orthofix Medical, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. With a market capitalization of USD 477 million, the company faces challenges in profitability and has experienced a decrease in profits, underperforming against the S&P 500.
Orthofix Medical Forms Golden Cross, Signaling Potential Bullish Breakout
Orthofix Medical, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has outperformed the S&P 500 in daily and weekly performance, despite a year-to-date decline. Technical indicators suggest a positive trend, though challenges remain in the broader market context.
Orthofix Medical, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Orthofix Medical, Inc. has experienced notable stock fluctuations, closing at $14.71 with a 52-week range of $10.24 to $20.73. Technical indicators present mixed signals, while the company's performance has lagged behind the S&P 500, showing a significant decline over the past year and five years.
Is Orthofix Medical, Inc. technically bullish or bearish?
As of September 19, 2025, Orthofix Medical, Inc. is in a mildly bearish trend, with daily moving averages and monthly indicators signaling weakness, while the stock has underperformed the S&P 500 with a year-to-date return of -14.89% compared to the index's 13.31%.
Is Orthofix Medical, Inc. technically bullish or bearish?
As of September 19, 2025, Orthofix Medical, Inc. has shifted to a mildly bearish trend, with daily moving averages and monthly indicators signaling bearish sentiment, despite some weekly bullish signals, and the stock has underperformed the S&P 500 with a return of -9.75%.
Is Orthofix Medical, Inc. technically bullish or bearish?
As of July 21, 2025, Orthofix Medical, Inc. shows a mildly bearish trend with mixed technical indicators, including bullish weekly MACD and Bollinger Bands, but mildly bearish daily moving averages and KST, suggesting caution in the overall outlook.
Is Orthofix Medical, Inc. overvalued or undervalued?
As of April 30, 2021, Orthofix Medical, Inc. is considered a risky investment due to its negative performance metrics and disappointing stock returns, indicating it is overvalued compared to its peers and the S&P 500.
Is Orthofix Medical, Inc. overvalued or undervalued?
As of April 30, 2021, Orthofix Medical, Inc. is considered overvalued and risky, with significant financial distress indicated by negative key ratios and a year-to-date return of -38.14%, underperforming the S&P 500.
Is Orthofix Medical, Inc. technically bullish or bearish?
As of May 6, 2025, Orthofix Medical, Inc. exhibits a bearish trend, supported by bearish MACD signals, moving averages, and Bollinger Bands, indicating significant weakness compared to the S&P 500.
Who are in the management team of Orthofix Medical, Inc.?
As of March 2022, the management team of Orthofix Medical, Inc. includes Independent Chairman Ronald Matricaria, CEO Jon Serbousek, and Independent Directors Jason Hannon, James Hinrichs, Alexis Lukianov, Lilly Marks, and Michael Paolucci. They oversee the company's operations and strategic direction.
What does Orthofix Medical, Inc. do?
Orthofix Medical, Inc. is a global medical device company specializing in reconstructive and regenerative orthopedic and spine solutions. As of March 2025, it reported net sales of $194 million and a market cap of $412.18 million.
How big is Orthofix Medical, Inc.?
As of Jun 18, Orthofix Medical, Inc. has a market capitalization of 412.18 million and reported net sales of 804.54 million with a net profit of -143.07 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
